SCYNEXIS-Aktien steigen über 30 % aufgrund der wachsenden Sorge um die Ausbreitung von Candida auris und möglicher Arzneimittelresistenz
Does Cidara Therapeutics (CDTX) have what it takes to be a top stock pick for momentum investors? Lets find out.
BOSTON, March 25, 2025 (GLOBE NEWSWIRE) -- Bicara Therapeutics Inc. (Nasdaq: BCAX), a clinical-stage biopharmaceutical company committed to bringing transformative bifunctional...
The consensus price target hints at a 64.5% upside potential for Cidara Therapeutics (CDTX). While empirical research shows that this sought-after metric is hardly effective,...
